Companies benefitting from the rising trend of peptide usage.
Landscape of Public Companies Benefiting from Increased Peptide Usage (Excluding GLP-1-Only Demand)
This landscape organizes companies by supply chain position and impact type to illustrate how increased peptide (non-GLP-1) usage is driving growth across the market. Companies are grouped into:
- Direct Peptide/API Manufacturers & Developers
- Drug Delivery & Injectable Packaging
- Bioprocessing, Tools & Analytical Solutions
- Software/Modeling & Services
- Biologics/Advanced Therapy Enablers
1. Direct Peptide/API Manufacturers & Developers
| Ticker | Company Name | Market Cap | Evidence of Benefit | Impact Type |
|---|---|---|---|---|
| RDY | Dr. Reddy’s Laboratories | $11.95B | Building peptide capacity for 40+ peptides, third-party manufacturing, CapEx in peptides | Direct API/peptide manufacturing, capacity expansion |
